JN-International Medical Corporation Acquires Biocor Vaccine Facilities from Pfizer, Inc.

Share Article

One of the world's leading Biopharmaceutical Companies, JN International, announced it is to expand its ability to increase vaccines supplies by acquiring a vaccine research and production facility from Biocor, a subsidiary of Pfizer Inc., in Omaha.

One of the world's leading Biopharmaceutical Companies, JN International, announced it is to expand its ability to increase vaccines supplies by acquiring a vaccine research and production facility from Biocor, a subsidiary of Pfizer Inc., in Omaha.

The state-of-the-art vaccine manufacturing facility consists of 3 buildings at 2721 N. 84th, 2704 N. 84th, and 2720 N. 84th Street, Omaha, Nebraska 68134, which are approximately 80,000 sq. ft., in total combined space. These facilities were designed for the manufacture of vaccines. The purchase represents a significant capital investment by JN International, which is intended to help significantly reduce time-to-market for the firm's Meningococcal meningitis serotypes A, C, Y & W-135 vaccine and increase production capacity to meet the demand of sub-Saharan Africa and South East Asia said Dr. Jeeri R. Reddy, the President and Scientific Director of the corporation.

"Vaccines have always been an integral part of JN's business and our contribution to public health and saving lives and the startup of this new facility in Omaha intends to provide quality vaccines that prevent diseases and enhance health care for millions around the world. Vaccination prevents millions of deaths per year, and yet millions more are dying due to the lack of vaccines. Stringent regulatory hurdles and the perception of moderate returns on investment have not encouraged companies like us to enter the markets faster. Prevention is better than cure--innovation of new vaccines for healthcare make a real difference for the world. To realize this goal, we recognize that JN resources and capabilities are necessary, but not sufficient--we just can't do it alone. Successful, productive partnerships are essential for JN's ongoing pursuit of innovation and excellence," said Dr. Reddy.

"Currently, Meningococcal vaccine contains serogroups A, C, Y and W-135 and is badly required by sub-Saharan Africa," said Dr. Noel Kouame, Medical Director of JN-International in Côte d'Ivoire. "Manufacturers globally produce less vaccine than is required annually. Actual requirement and demand exceed greatly the current production. The supply of Meningococcal vaccines, be it in response to a pandemic or seasonal outbreaks in Africa, requires robust production processes supported by manufacturers with stringent supply chain routines and quality systems who are able to react quickly to the demand. With vaccine candidates, improved processes and increased capacity, vaccine manufacturers are better prepared, but there is still some way to go to meet the goals of JN operations in West Africa."

JN-International Medical Corporation:
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. An Inc 5000 corporation, making it the 95th ranking company in the United States and the 3rd biopharmaceutical global corporation, it produces Meningitis vaccine for which it holds the international intellectual property rights (IPR).

JN boasts a decade of achievements including prevention of mother-to-child transmission of HIV in South East Asia, development of inexpensive vaccine for Meningococcal meningitis serogroups A, C, Y&W-135 and lately the discovery of a new generation preventive and therapeutic vaccine for Stroke and neurological disorders.
The R&D division of JN-International is currently researching and developing vaccines for the prevention and cure of Hepatitis C, Herpes, Tuberculosis and a preventive and therapeutic vaccine for Stroke.
JN-International Medical Corporation (JNI), based in Omaha, Nebraska, USA has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore.

For more information:
Contact:
Peter Grotzinger, director of public relations
JN-International Medical Corporation
402-884-3477
http://www.jn-vaccines.org

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website